摘要
目的:通过观察冬虫夏草提取物对糖尿病肾病(DN)患者的临床治疗以及该药物对肾小球系膜细胞TGF-β1基因的影响,探讨冬虫夏草提取物在延缓DN进展过程中的作用机制及疗效。方法:以糖尿病肾病患者为研究对象,应用冬虫夏草发酵菌粉治疗,观察中医症候改善情况以及临床实验室指标。同时运用细胞培养人肾小球系膜细胞(HMC)方法,观察高糖刺激下HMC的增殖变化,并运用冬虫夏草发酵菌粉药物血清进行体外干预,运用反转录RT-PCR方法检测TGF-β1基因。结果:冬虫夏草提取物联合缬沙坦治疗DN明显改善患者中医症候并显著降低UAER。药物血清干预后24h和48h,在相同作用时间各组与高糖组比较(P<0.01),高糖培养mRNA的表达增加,明显高于正常对照组(P<0.05)。结论:冬虫夏草发酵菌粉明显改善DN患者中医症候,降低患者尿蛋白,可能与其下调TGF-β1基因表达延缓肾小球硬化有关。
Objective：To investigate the effects of Dongchong Xiacao on Patients with DN andHMCs cultured in vitro.Methods：Observe the symptomatology of TCM in patients valsartan treatment and Dongchong Xiacao capsule.At the same time we got the rats serum with different concentrations of medicine,and then we studied the effects of the serum on HMCs.RT-PCR was used to detect the expressions of TGF-β1mRNA.Result： The expression of TGF-β1mRNA of the Dongchong Xiacao were lower than those in high glucose group（P〈0.05）.Conclusion：Dongchong Xiacao can not only inhibit symptomatology of TCM in patients but also can decrease the secretion of TGF-β1,so it can delay the progression of DN.
出处
《中医药学报》
CAS
2013年第3期154-156,共3页
Acta Chinese Medicine and Pharmacology
基金
黑龙江省中医药管理局(No.ZHY12-W063)
